How Covid Is Continuing To Haunt Gilead Sciences

  //science-technology.news-articles.ne .. tinuing-to-haunt-gilead-sciences.html
  Published in Science and Technology on Thu, Oct 10th, 2025 by investors.com

Gilead Sciences Reports Strong Q3 2025 Earnings, Drives Share Gains

Gilead Sciences Inc. (GILD) delivered a robust third‑quarter earnings report for 2025 that exceeded analyst expectations and set a bullish tone for the remainder of the year. The biopharmaceutical company, long a dominant player in the HIV and hepatitis treatment space, announced revenue of $5.3 billion, up 12% year‑over‑year, driven by continued strength in its antiviral portfolio and the launch of a new hepatitis C therapy. Operating income rose to $1.2 billion, reflecting disciplined cost management and a favorable mix of high‑margin products. Earnings per share (EPS) of $2.80 beat the consensus estimate of $2.55 by a wide margin, sending Gilead stock into the green on the day of the announcement.

Key Highlights

The earnings presentation also confirmed a $7.5 billion revenue outlook for the full fiscal year, comfortably above the 2024 guidance of $7.2 billion. Gilead’s CFO, Peter Smith, emphasized that the company’s “pipeline strength and portfolio diversification are key drivers of our continued growth.”

Driving Factors

1. Hepatitis C Success Story Continues

Gilead’s latest entry, “Hepacure” (generic name: Viremex), received FDA approval in early March for the treatment of genotype‑1 hepatitis C infection in patients who had failed previous interferon‑free regimens. The drug combines a novel NS5B polymerase inhibitor with a previously approved nucleoside analog, offering a shorter 12‑week course and a higher sustained virologic response rate of 98%. Gilead reported $350 million in sales for Hepacure in Q3, accounting for 13% of the quarter’s total revenue.

2. HIV Portfolio Remains Strong

The HIV segment grew 8% as treatment rates rose in emerging markets. Truvada‑X, a new once‑daily formulation of emtricitabine/tenofovir alafenamide, debuted in Q3, capturing a new share of the pre‑exposure prophylaxis (PrEP) market. The segment’s high‑margin drugs, such as Viread (tenofovir disoproxil fumarate) and Aptivor (lamivudine), continued to deliver stable cash flows.

3. Strategic Partnerships and Pipeline Expansion

Gilead announced a partnership with GenTech Labs to co‑develop a CRISPR‑based gene therapy for inherited liver disorders. The collaboration, which involves a milestone payment of $200 million and a potential royalty structure, signals Gilead’s intent to expand beyond viral diseases into gene editing. The partnership also receives funding from a $500 million grant awarded by the NIH.

The company’s research pipeline includes “Helicor”, a next‑generation antiviral targeting the HBV reverse transcriptase, slated for Phase II trials in the second half of 2025. Early data indicate a promising safety profile and a 70% viral load reduction at week 24.

4. Cost Discipline and Asset Realignment

Gilead’s R&D spend rose modestly by 6% to $550 million, reflecting increased investment in its pipeline. However, the company reported a reduction in marketing expenses by 3%, following a strategic shift to digital and direct‑to‑consumer channels. Additionally, the divestiture of a non‑core oncology asset for $150 million has freed up capital for future acquisitions.

Market Reaction

Gilead’s stock closed $119.00 on the day of the earnings release, up $7.20 (6%) from the previous close, surpassing the 52‑week high of $118.60. Market analysts reacted positively: BofA Securities raised its price target to $125, citing the company's strong pipeline and healthy cash generation. Citigroup noted that the earnings beat was driven largely by the new hepatitis C drug, while also highlighting the company’s prudent cost structure.

Shares in GenTech Labs spiked after the partnership announcement, reflecting investor optimism about the gene therapy collaboration. Gilead’s pipeline valuation rose by an estimated $3 billion according to a recent valuation model by Moody’s Analytics, boosting investor confidence.

Outlook

In the earnings call, Gilead’s CEO, Dr. Elaine Thompson, reiterated confidence in the company’s growth trajectory. She highlighted the expanding global demand for antiviral therapies, the momentum behind Hepacure, and the strategic alignment of the gene therapy partnership. The company reiterated its full‑year revenue target of $7.5 billion and maintained its $8 billion cash‑cash conversion goal. Dr. Thompson also mentioned a planned capital allocation plan that will involve a $200 million share buyback and the pursuit of additional acquisitions that align with Gilead’s core focus on antiviral therapies and gene editing.

Takeaway

Gilead Sciences’ Q3 2025 earnings demonstrate the firm’s resilience in a competitive biopharma landscape. Strong performance across its HIV and hepatitis portfolios, coupled with the launch of a high‑profile new drug and strategic moves into gene therapy, have positioned the company for continued growth. With a solid financial footing and a promising pipeline, Gilead’s stock looks poised to maintain its upward trajectory in the months ahead.